Request Sample
Request Methodology
Description
Foodborne Diseases Treatment Market size was valued at USD x billion in 2021, growing at a CAGR of x% from 2022-28. Foodborne diseases cover a broad spectrum of illnesses that are affecting the people worldwide. These diseases are due to the intake of food contaminated with harmful microorganisms or chemicals. The contamination occurs from any way either soil, water or air. The most common foodborne infections are caused by three bacteria campylobacter, salmonella, and E.coli and by a group of viruses called calicivirus. Clinical symptoms of foodborne diseases seen in gastro intestinal tract. Symptoms include vomiting, diarrhea, and abdominal pain. In some cases, such diseases can also have neurological, gynecological, immunological and other symptoms. Common foodborne diseases include botulism, salmonellosis, traveler’s diarrhoea, gastroenteritis, tapeworm infection and hepatitis A, among others. Global foodborne diseases treatment market is driven by the increasing incidence of foodborne diseases worldwide. According to the findings of WHO – “Estimates of the global burden of foodborne diseases” 2015, almost 1 in every10 people fall ill yearly due to contaminated food consumption and 420,000 deaths occour as a result. Market players are adopting drug developments and collaborations as key market strategies. The report market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).
Key Developments:
In 2015, January, Valneva SE, entered a purchase and sale with Crucell Holland B.V. in order to acquire Crucell Sweden AB and privileges and licenses of dukoral vaccine to treat cholera and traveler’s diarrhea.
